Gates Package — page 253

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Walter Koroshetz, M.D. Director National Institute of Neurological Disorders and Stroke, NIH Lisa LaVange, Ph.D. Professor and Associate Chair, Department of Biostatistics University of North Carolina Gillings School of Global Public Health Elliot Levy, M.D. Senior Vice President, Global Development Amgen John Mellors, M.D. Distinguished Professor of Medicine, Chief of Division of Infectious Diseases University of Pittsburgh School of Medicine Sandeep Menon, M.D., Ph.D. Senior Vice President and Head of Early Clinical Development Pfizer Naimish Patel, M.D. Head of Global Development, Immunology and Inflammation Therapeutic Area Sanofi Amanda Peppercorn, M.D. Senior Medical Director, Infectious Disease GlaxoSmithKline Mike Poole, M.D., FACP Therapeutic Accelerator Lead Bill & Melinda Gates Foundation Michael Proschan, Ph.D. Mathematical Statistician, Biostatistics Research Branch National Institute of Allergy and Infectious Diseases, NIH Sarah Read, M.D. (Co-Chair) Deputy Director, Division of AIDS National Institute of Allergy and Infectious Diseases, NIH Lora Reineck, M.D., M.S. Program Director, Acute Lung Injury/Critical Care Program, Division of Lung Diseases National Heart, Lung, and Blood Institute, NIH Yves Rosenberg, M.D., M.P.H. Chief, Atherothrombosis and Coronary Artery Disease Branch National Heart, Lung, and Blood Institute